

NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING

AGENDA

OPEN SESSIONS

Venue: Carlyle

Date: Saturday, May 1st 2011

Time: 8:30 a.m. – 12:00 p.m.

Chair: Dr. Warren Mason

8:30 am **WELCOME AND INTRODUCTIONS**

W. Mason

NEW CONCEPTS/PROPOSALS FOR ENDORSEMENT

8:35 am **ECOG E3F05:** Phase III study of radiotherapy +/- temozolomide for symptomatic or progressive low-grade gliomas

D. Schiff (ECOG)

9:00 am **NCCTG N107C:** A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease

P. Brown (NCCTG)

COMPLETED STUDIES

9:30 am **IND.162:** A Phase I/II study of Temozolomide and RAD001c in Patients with Malignant Glioblastoma Multiforme
Final report and manuscript status

W. Mason

TRIALS CLOSED TO ACCRUAL

9:40 am **CE5 (EORTC 22033-26033):** Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study

W. Mason

CE.5S: The Socio/behavioural Effects of Primary Chemotherapy with

Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study

A. Leis & M. Parkinson

Brain Disease Site Committee Learning Objectives

- To understand and address, through clinical and translational research, the disease burden associated with CNS malignancies Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to CNS malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group relevant to CNS malignancies.
- To understand and apply new clinical trial methodologies in the field of clinical research in CNS malignancies.

ACTIVELY ACCRUING TRIALS

- 9:50 am **CE.6:** A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients N. Laperriere & J. Perry
- 10:00 am COFFEE BREAK
- 10:15 am **CEC.1 (EORTC 26053_22054):** Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial W. Mason & C. O'Callaghan
- 10:30 am **CEC.2 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (CODEL Trial) G. Cairncross & C. O'Callaghan
- 10:45 am **IND.204:** PX866 in Recurrent GBM M.Pitz

SPECIAL SESSION -TERRY FOX RESEARCH INSTITUTE (TFRI) PROPOSAL: THERAPEUTIC TARGETING OF GBM

- 11:00 am Project Overview G. Cairncross
- 11:10 am Translational Research Program A. Luchman
- 11:40 am Role of NCIC CTG Brain and IND sites in conducting early phase clinical trials of promising new drugs for GBM E. Eisenhauer & W. Mason

12:00 p.m. Closing Remarks

Brain Disease Site Committee Learning Objectives

- To understand and address, through clinical and translational research, the disease burden associated with CNS malignancies Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to CNS malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group relevant to CNS malignancies.
- To understand and apply new clinical trial methodologies in the field of clinical research in CNS malignancies.